Mapi Pharma Ltd. announced that it has entered into a security purchase agreement for private placement of maximum of 92,590,000 shares at not more than $10.80 per share for gross proceeds of $10,000,000 on January 3, 2016. The transaction will include participation from new investor Zhejiang Jingxin Pharmaceutical Co., Ltd. (SZSE:002020).